Rye whole grain and bran intake has shown beneficial effects on prostate cancer progression in animal models, including lower tumor take rates, smaller tumor volumes, and reduced prostate specific antigen (PSA) concentrations. A human pilot study showed increased apoptosis after consumption of rye bran bread. In this study, we investigated the effect of high intake of rye whole grain and bran on prostate cancer progression as assessed by PSA concentration in men diagnosed with prostate cancer. Seventeen participants were provided with 485 g rye whole grain and bran products (RP) or refined wheat products with added cellulose (WP), corresponding to ;50% of daily energy intake, in a randomized controlled, crossover design. Blood samples were taken from fasting men before and after 2, 4, and 6 wk of treatment and 24-h urine samples were collected before the first intervention period and after treatment. Plasma total PSA concentrations were lower after treatment with RP compared with WP, with a mean treatment effect of 214% (P = 0.04). Additionally, fasting plasma insulin and 24-h urinary Cpeptide excretion were lower after treatment with RP compared with WP (P , 0.01 and P = 0.01, respectively). Daily excretion of 5 lignans was higher after the RP treatment than after the WP treatment (P , 0.001). We conclude that whole grain and bran from rye resulted in significantly lower plasma PSA compared with a cellulose-supplemented refined wheat diet in patients with prostate cancer. The effect may be related to inhibition of prostate cancer progression caused by decreased exposure to insulin, as indicated by plasma insulin and urinary C-peptide excretion.
Introduction
Prostate cancer is the second most common cancer among men worldwide, but there is a large variation in incidence and mortality between regions. Although prostate cancer tumors have been shown to be affected by inherited genetic factors to a greater extent than many other tumors, higher incidence rates have been observed among immigrants from Asia to Western countries compared with those who did not move, suggesting that lifestyle and environmental factors are also important (1, 2) .
Diet is likely to affect both the incidence and progression of prostate cancer, but the relationships to individual foods and nutrients are not simple and are probably modified by genetic factors (3, 4) . Reduced energy intake and intake of phytoestrogens (isoflavonoids, lignans, and coumestans) and micronutrients such as a-tocopherol, selenium, lycopene, vitamin D, and polyphenols have been shown to have beneficial effects on prostate cancer incidence and mortality in observational studies (3, 5, 6) . Several human intervention studies have investigated the effects of dietary components on prostate cancer progression and have evaluated potential mechanisms of action, including effects on insulin secretion, modulation of the insulin-like growth factor 1 (IGF-1) 9 system, sex hormone availability and activity, and free radical damage (7) (8) (9) (10) (11) , but the results have been inconclusive. Recently, prostate cancer has been suggested to be a component of metabolic syndrome (12) and population studies have linked hyperinsulinemia to adverse outcomes in prostate cancer (13, 14) . Whole grain is a rich source of fiber and bioactive compounds, including tocols, B vitamins, minerals, dietary fiber, phenolic acids, and phytoestrogens (15) . Intake has been consistently associated with reduced risk of chronic diseases such as cardiovascular disease, type 2 diabetes, and certain cancers (16) (17) (18) (19) . The role of whole grain in prostate cancer is unclear due to a lack of studies. Epidemiological studies on dietary fiber and fiberrelated phytochemicals, including phytoestrogens, have been conducted, but the results are conflicting (20) . A small human pilot study in men with prostate cancer showed that a diet rich in rye bran bread resulted in higher apoptosis in men with prostate cancer after 3 wk but no changes in prostate specific antigen (PSA) compared with a refined wheat control diet (21) . Animal studies have shown reduced PSA concentrations and tumor volumes in mice with LNCaP tumor implants after rye bran treatment (22) . Moreover, rats with prostate adenocarcinoma implants had slower early tumor growth when fed a diet containing 33.3% rye bran compared with a refined wheat control diet (23) . PSA is regarded as one of the best currently available biomarkers for prostate cancer progression (24) and has been used in several dietary intervention studies (8) (9) (10) (11) 25) .
Encouraged by the results from the human pilot intervention study and animal experiments, we decided to investigate whether a diet rich in whole grain and bran rye products compared with refined wheat products with added cellulose could affect the progression of prostate cancer, as measured by PSA concentration in men with early stage prostate cancer. To assess potential mechanisms, we also investigated the effects on circulating and excreted phytoestrogens (lignans), insulin secretion (24-h urinary C-peptide excretion, plasma insulin, and glucose concentrations), and low-grade systemic inflammation measured by high-sensitive C-reactive protein (hsCRP).
Materials and Methods
Participants and study design. Twenty-four men with clinically diagnosed prostate cancer were recruited for this study, which was conducted on an out-patient basis in a randomized crossover design with two 6-wk intervention periods separated by a 2-wk washout period. The participants were not informed about the order of treatments, but products appeared somewhat different and therefore they may have guessed what treatment they received. The men had chosen not to undergo any conventional treatment and had low risk prostate cancers, as defined by the Gleason score and tumor stage (according to the tumor spread to lymph nodes and metastasis staging system). The treatments were a diet rich in rye whole grain and bran products (RP) or refined wheat grain products with added cellulose (WP). Treatment effects were evaluated after 2, 4, and 6 wk and compared within-participant mean for the whole treatment period between treatments. Only men with histologically confirmed prostate tumors and no other tumors (except skin tumors) were included in the study. Moreover, men undergoing other treatments for prostate cancer during the time of the study were excluded. For logistical reasons, the study was carried out on 3 occasions between April and July 2005, with the treatment order separately randomized on each occasion. Seven participants dropped out of the study mostly due to constipation problems, maybe related to the inability to adapt to the high-dietary fiber content of the diets. Seventeen men completed the whole study and provided complete data records from 3 occasions. On the first occasion, 2 men started with RP and 3 men started with WP; on the second occasion, 5 men started with RP and 3 started with WP; and on the 3rd occasion, 2 men started with RP and 2 with WP.
Diet. Participants were instructed by a dietician to keep their habitual diet except for bread, porridge, muesli, and other fiber-or lignan-rich foods and table spreads, which were replaced by products provided by the study (intervention foods). During treatment periods, the men were asked to include intervention foods as part of their breakfast, lunch, dinner, and 2-3 snacks/d. The intervention foods consisted of 300 g/d soft bread (5 pieces), 100 g/d crisp bread (10 pieces), 50 g/d breakfast cereals, 35 g/d porridge (uncooked), and 58 g/d table spread. Rye whole grain and bran products and refined wheat products for the respective treatments were provided by Wasabrö d and Lantmä nnen. The foods used were designed specifically for the purpose of the present study, with the aim of providing the same macronutrient profile ( Table 1) . To obtain the same fiber content in intervention foods for both treatments, purified wheat cellulose (Vitacel) was added to the refined wheat products and a table spread was provided to avoid differences in fat quality between treatments. To ensure compliance, a dietician or a nurse had regular telephone contact with the participants. Participants completed 4-d weighed food records before treatment period 1 and at the end of each treatment to allow nutrient and total energy intake to be calculated and as the main assessment of compliance. The difference between distributed and consumed intervention foods as well as measurement of plasma total alkylresorcinol concentration, a novel biomarker of whole grain and bran intake (26), were used as additional assessments of compliance. Nutrient and energy intake were calculated from intervention product labels and by using the food database of the Swedish National Food Administration (PC-Kost 1.99, SLV) and the software program MATs 4.05 (Rudans Lä ttdata).
Blood and urine collection. A total of 8 blood samples were collected from fasting men before treatments and after 2, 4, and 6 wk of treatment. Blood drawn from an antecubital vein was collected in EDTA-coated vacuum tubes, which were immediately centrifuged at 2000 3 g; 10 min at 48C to separate plasma, buffy coat, and erythrocytes. Plasma samples were portioned into 2-mL cryotubes and stored at 2808C until analysis. Twenty-four-hour urine samples were collected on the day before intervention period 1 and on the last day of each intervention in 24-h urine collection containers. Collected urine was preserved with ascorbic acid to prevent oxidation and stored at 2208C until analysis.
Laboratory assays. Total and free PSA were analyzed by the Wallac Prostatus PSA Free/Total Autodelfia assay (PerkinElmer-Wallac). The detection limit for total PSA was 0.1 mg/L and that for free PSA was 0.01 mg/L. In the concentration range 0.5-50 mg/L, the intra-assay CV was ,4.3-8.8% for total PSA and 4.1-7.8% for free PSA (27) . C-peptide in urine samples was quantified by immunoassay (C-peptide ELISA, Mercodia). The within-and between-batch CV were ,5%. High sensitivity C-reactive protein (hsCRP) was measured in serum by an ultrasensitive particle enhanced immunoturbidimetric assay (Orion Diagnostica) on a Konelab 20 autoanalyzer (Thermo Clinical Labsystems). Within-and between-batch CV were ,5%. Plasma glucose was analyzed by the glucose oxidase method with an auto analyzer (Abbott). Within-and between-batch CV were ,10%. Serum insulin was measured by an immunoassay (Boehringer Mannheim). Within-and between-batch CV were ,10%.
The concentration of plasma alkylresorcinol homologs C17:0-C25:0 and their sum was analyzed by GC-MS according to Landberg et al. (28) . Within-and between batch CV of a control sample included in quadruplicate in every batch were ,8 and ,10%, respectively. The content of 6 lignans [medioresinol (MED), lariciresinol, matairesinol (MAT), pinoresinol, secoisolariceresinol (SECO), and syringaresinol] in the intervention foods was analyzed according to Penalvo et al. (29) . The within-and between-batch CV were 3-13% and 4-11%, respectively, for the different lignans. Five lignans in urine [MAT, SECO, hydroxymatairesinol (HMR), enterodiol (END), and enterolactone (ENL)] were analyzed according to Nurmi et al. (30) and the within-and between-batch CV ranged from 4 to 16% and 11 to 36%, respectively. High between-batch CV for some plant lignans was due to very low concentration in control samples (30) . ENL in plasma was analyzed according to Peñ alvo et al. (31) . Within-and between-batch CV were 4-12% and 4-6%, respectively, for high-low samples. Plasma tocopherols were analyzed according to Kamal-Eldin et al. (32) , but smaller volumes of sample, hexane, and ethanol were used in the present method (0.2, 0.8, and 0.2 mL, respectively). The within-and between batch CV were ,10%.
Statistics. SAS version 9.1 (SAS Institute) was used for all statistical calculations. Response variables were log-transformed when distributions were skewed (Shapiro-Wilks test, P , 0.05). This was the case for P-glucose, P-CRP, C-peptide in urine, and all lignans. Treatment effects were evaluated with linear random effect models using PROC Mixed. Treatment (RP or WP), sequence, and period were included as fixed factors and participant as a random factor in the models. For body weight, PSA, plasma glucose, plasma insulin, and plasma CRP baseline values were included as covariates in the models. For the other effect variables, baseline values were not available. Carryover effects were tested by replacing sequence for a period-treatment interaction term in the models. All effects with P , 0.05 were considered significant, except for the evaluation of carryover effects, where P , 0.10 was considered significant because of the lower statistical power of that comparison. Paired t tests were used to compare energy, fat, dietary fiber and protein intake, body weight, C-peptide excretion, and PSA concentrations between the treatment periods and baseline. The baseline characteristics of participants are presented as means 6 SD, whereas treatment means are least square means 6 SE or geometric means (95% CI) (when data were log-transformed) unless otherwise stated. All statistical tests were 2-sided.
Results
Diets and compliance. All participants were nonsmokers and reported no use of dietary supplements or medications. Their age (mean 6 SD) was 73.5 6 4.6 y and BMI was 27.5 6 4.6 kg/m 2 . There were some differences in baseline characteristics according to treatment sequence, but these differences were compensated for because all men served as their own controls ( Table 2) .
Overall, participants who completed the study complied well with consuming the advised foods, although intake did not fully reach the advised amounts for breads and crisp breads, as determined by the difference between provided and remaining food products and by food records ( Table 3) . However, the difference was consistent and similar for the 2 treatments. Additionally, plasma total alkylresorcinol concentration, a novel biomarker of wheat and rye whole grain and bran intake, which was analyzed as an independent measure of compliance after 2, 4, and 6 wk within each treatment, remained stable within individuals over the 2 treatment periods (within-participant CV was 11 and 9% for the respective treatment periods), confirming good compliance and regular intake as instructed (26) . We observed no differences in plasma a-or g-tocopherol concentrations between the 2 treatments (data not shown). Because energy intake may affect prostate cancer progression, the intervention foods were designed to contain about the same energy content and sufficient energy was provided to prevent a decrease in weight. As a consequence, total energy intake, estimated by 4-d weighed food records, did not differ significantly between the treatment periods. Intake during both treatment periods was ;20% greater than at entry in the study (P , 0.01). Body weights did not differ significantly between the treatment periods after 2, 4, and 6 wk or when overall means were compared. However, body weights after 2, 4, and 6 wk of consuming the RP diet in the second period were ;2% less than at baseline (P = 0.04). Body weight did not change from baseline after the first period for either treatment or for the WP diet after the second period. Moreover, total fat and protein intakes did not differ between treatments and baseline, but the dietary fiber intake was very high and differed from baseline for both treatments in both periods (P , 0.05). Several men (n = 7) did not complete the study because of constipation; among participants completing the study (n = 17), mild constipation was reported in some cases. This shows that some men may not tolerate such a high-dietary fiber intake, at least not without a longer adaptation period. This observation should be taken into account when designing future studies.
Lignan intake and excretion. The content of the 6 lignans analyzed in intervention foods was 50-100 times higher in rye whole grain and bran intervention foods compared with refined wheat intervention foods ( Table 2 ). The advised and estimated daily total lignan intake was 12.9 and 11.4 6 1.3 mg, respectively, during the RP treatment and 0.7 and 0.6 6 0.1, respectively, during the WP treatment ( Table 3 ). The plasma ENL concentration (geometric mean) was 18 nmol/L (95% CI: 12, 28 nmol/L) after RP and 6 nmol/L (95% CI: 4, 10 nmol/L) after WP. As expected, excretion of both mammalian lignans (ENL and END) and 3 plant lignans (secoisolariciresinol, HMR, and matairecinol) was significantly higher after the RP treatment than after the WP treatment ( Table 4 ). The lignan excretion (geometric mean) corresponded to ;22% of the mean daily intake of the 6 lignans (Tables 3 and 4) .
PSA. The plasma total PSA was lower after 2 wk of the RP treatment than after the WP treatment (P = 0.02) and the mean effect of the 6-wk treatment periods was about 214% (P = 0.04) ( Table 5 ; Supplemental Fig. 1 ). Total PSA did not change from baseline, although it tended to be lower after 2 wk of the RP 1 Values are means 6 SD, n = 17. 2 Food/macronutrient provided by the experimental diet minus the amount left after treatment. 3 Total daily intake of foods or macronutrients (intervention foods + habitual diet) reported by 4-d weighed food records are given within brackets. 4 Intakes of saturated and unsaturated fat from the habitual diet + table spread did not differ between treatments when using mixed linear models with log-transformed saturated or unsaturated fat intake as dependent variables. Diet, period, and sequence were entered as fixed factors and participant as random factor. 5 Energy intake (kJ/d) reported as the sum of energy from fat (37 kJ/g), protein (17 kJ/g), carbohydrates (17 kJ/g), and dietary fiber (8 kJ/g). Values are geometric means (95% CI); n = 17. Zero-values were replaced by the value corresponding to the limit of detection of the method (30) . 2 Treatment effects (difference between RP and WP) were evaluated with mixed linear models with treatment, sequence, and period as fixed factors and subject as random factor. No significant carryover effects were found when sequence was replaced with an interaction term of diet 3 period. *P , 0.05, **P , 0.01, ***P , 0.001. 3 Sum of MAT, SECO, HMR, END, and ENL. 4 Sum of END and U-ENL. treatment in the first period (P = 0.08). Free PSA and free:total PSA did not differ after the RP treatment compared with WP treatment.
Urinary C-peptide, plasma insulin, and hsCRP. The insulin secretion (geometric mean) measured as C-peptide excretion in 24-h urine collections was 20.7 mmol/d (95% CI: 15.0-28.6) after the RP treatment and 28.9 mmol/d (95% CI: 20.9-39.9) after the WP treatment, i.e. there was a 28% difference between treatments (P , 0.01). C-peptide excretion decreased from baseline after the RP treatment in both periods (P , 0.05), but there was no change after the WP treatment. Plasma insulin differed after the RP (6.8 pmol/L, 95% CI: 5.1, 9.1) and WP (7.7 pmol/L, 95% CI: 5.8, 10.3) periods when the means of wk 2, 4, and 6 were compared (P = 0.04), but the plasma glucose concentration did not (Table 5) . Plasma CRP concentrations were lower within 2 wk of the RP compared with the WP treatment (P = 0.03). Based on withinparticipant means for the respective treatments, the difference tended to be significant (P = 0.05) ( Table 5 ).
Discussion
Treatment effects on PSA. In this study, 6-wk intervention with RP caused a 14% reduction in total PSA compared with WP (P = 0.04). No previous study, to our knowledge, has demonstrated an effect of whole grain and bran compared with refined grain on PSA in humans, but this finding is supported by results from animal models.
Lower PSA concentrations have been shown in mice with LNCaP tumor implants within 3 and 6 wk of rye bran treatment compared with a WP control (22) . In another study, tumor take rate and tumor volume were lower after rye bran treatment compared with a refined wheat control and tumor volume was correlated to PSA concentrations (r = 0.68; P , 0.001). Similar results were found in rats with highly differentiated Dunning R33327 PAP tumors after a rye bran diet compared with those in rats fed a control diet (23) . In a human study, Bylund et al. (21) found no changes in PSA, tumor epithelial cell proliferation, or apoptotic index between rye bran bread and WP treatments, but they observed an increase in the apoptotic index after rye treatment compared with baseline. In contrast, we observed no differences in tumor progression (indicated by PSA) compared with baseline in the present study, which may be due to the already high intake of RP by the men at baseline, as indicated by a high dietary fiber intake from RP (;40% of total dietary fiber intake, ;9 g/d) (data not shown).
We recognize the possibility that the observed difference in the PSA concentration between the RP and WP treatment periods may be due to increased PSA concentration after WP rather than decreased concentration after RP or a combination. Increased PSA predicts clinical progression in the majority of men with prostate cancer and PSA kinetics over time is one of the strongest determinants of eventual treatment requirements in patients under surveillance (33) . A study with a longer duration would be required to investigate if PSA kinetics is altered with RP, WP, or both.
Treatment effects on insulin. Our results, showing a 28% lower C-peptide excretion and lower fasting plasma insulin concentration but no difference in fasting plasma glucose after RP compared with WP, are in agreement with results from a previous study where a high-fiber rye diet was compared with a low-fiber wheat diet in 10 human participants (34) . Several short-term rye bread intervention studies have shown diminished need for postprandial insulin to regulate plasma glucose and increased acute response of insulin, suggesting that rye may have positive effects on long-term insulin secretion and sensitivity (35, 36) . Lower insulin secretion may inhibit cancer progression and decrease PSA concentration directly by reducing the mitogenic activity of insulin or indirectly by decreasing hepatic production of IGF-1 and increasing that of IGF binding proteins (12) . IGF-1 affects cell proliferation, apoptosis, and tumorigenesis and is modulated by IGF binding proteins that control the availability of free IGF-I (37, 38) .
Treatment effects on inflammation. To our knowledge, no previous study has investigated the effect of a pure RP diet on hsCRP, but Katcher et al. (39) demonstrated a strong reduction in hsCRP in participants with metabolic syndrome fed a hypocaloric diet containing whole grain compared with a hypocaloric refined grain control diet for 12 wk. There are several possible explanations for the lower hsCRP concentration after the RP treatment compared with after the WP treatment in the present study, including a decrease in oxidative stress caused by antioxidants present in the RP or by reduced production of proinflammatory cytokines in adipose tissue, which has been demonstrated upon intake of whole grain rye foods (40) . Although inflammation is suggested to play a role in the etiology of prostate cancer (41) , large prospective studies have not shown any association (42, 43) .
Potential mechanisms of PSA reduction. The lower PSA concentration during the RP treatment is most likely not explained by changes in energy intake or body weight, both known risk factors for prostate cancer (14, 44) . However, the change may be related to lower energy utilization during the RP treatment and to some extent also during the WP treatment. This is supported by the fact that the men maintained stable weight or lost weight (22% after RP in the second treatment period only) during intervention compared with baseline despite the energy intake being~20% higher. Two previous studies in ileostomized participants have shown that considerable amounts of energy in the form of carbohydrates, proteins, and fats escaped digestion in the small intestine after consumption of rye bran and high-fiber rye breads compared with refined wheat breads (34, 45) . Mechanisms related to fermentation of components in the dietary fiber complex may explain the effect on tumor progression indicated by PSA in the present study. RP contain more soluble fiber than WP and is more readily fermented to SCFA, e.g. acetate, propionate, and butyrate (46) . About 3-fold higher plasma butyrate concentrations have been observed in pigs fed a rye diet with similar breads to those used in the present study compared with refined wheat breads (47) .
SCFA, particularly butyrate, were recently proposed to cause activation of hepatic AMP-activated protein kinase (AMPK), a major cellular fuel gauge and a master regulator of energy homeostasis in the body (48) . AMPK inhibits gluconeogenesis, resulting in lower hepatic glucose production and lower insulin secretion, and is the target of the antidiabetic drug metformin (49) . Like Hu et al. (49), we speculate that SCFA, particularly butyrate, produced by fermentation during the RP treatment may have caused activation of the hepatic AMPK and subsequent pathways, with lower insulin secretion as a result and hence less burden of direct and indirect effects of insulin on prostate cancer progression. Several observational studies in humans and animal studies have demonstrated an association between higher levels of insulin or C-peptide with adverse outcomes in prostate cancer (13, 14, 50) .
As a result of colonic fermentation, plant lignans are partly converted into the mammalian lignans ENL and END (51) . Lignan intake during the RP treatment was~10-fold higher than that found among a free-living Finnish population consuming large amounts of whole grain rye (52) . Lignans have been suggested to affect prostate cancer progression through different mechanisms, including modulation of sex/growth hormone metabolism, binding to sex hormone binding globulin, direct tumor inhibitory effects, and indirect effects through the IGF axis (51, 53, 54) . Lignans may have contributed to the effects on PSA, although any specific effect due to lignans could not be determined due to the design of our study.
The present study had several strengths and some limitations. First, the 6-wk cross-over design with repeated measurements within treatments enabled us to assess and detect small, intermediate-term treatment effects due to elimination of between-participant variation and reduction of within-participant variation. Second, the intervention foods provided the same macronutrient profile, and careful instructions and monitoring, including use of a novel biomarker of whole grain and bran intake, ensured that compliance by participants was good. Third, energy intake did not differ between the 2 treatments, but energy intake was higher during both treatments, eliminating the possibility of treatment effects due to lower energy intakes. The study also had some limitations, including lack of complete blinding and the small number of participants (n = 17), which had implications for the statistical power and increased the risk of chance findings. Moreover, we evaluated the effects of very high rye whole grain and bran intakes only in men diagnosed with prostate cancer and it remains to be tested if more normal intake levels would have effects that are of clinical importance and what role RP intake may have for the primary prevention of prostate cancer. Although our findings are supported by previous studies (21) (22) (23) , the results should be interpreted with caution and need to be confirmed in larger studies of longer duration. In conclusion, a diet rich in whole grain and bran of rye resulted in significantly lower plasma PSA compared with a diet rich in refined wheat products supplemented with cellulose. This effect may be related to an inhibition of prostate cancer progression caused by decreased exposure to insulin as measured by plasma insulin and C-peptide excretion. Future studies of longer duration are needed to confirm these results.
